Submission of Statement of Deviation & Variation.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories Limited has filed a routine compliance statement under SEBI (LODR) Regulation 32 for the quarter ended 31 December 2025. The company raised Rs. 281.98 Lakhs on 12 August 2025 through a public/preferential/QIP route for long-term funding needs including capital expenditure, working capital, and general corporate purposes. Of the total amount, Rs. 218.10 Lakhs has been utilized so far — Rs. 39.83 Lakhs in the September 2025 quarter and Rs. 178.27 Lakhs in the current December 2025 quarter. The company confirms there has been no deviation or variation in the use of funds, and both the Audit Committee and auditors had no comments. The filing was approved at the Board meeting held on 14 February 2026.
This is a routine regulatory filing with no negative signals — the company is using the raised funds as originally disclosed, which is reassuring for shareholders. No material price impact expected.